SLCO1B1: A Potential Drug Target and Biomarker (G10599)

Target Name: SLCO1B1

NCBI ID: G10599

SLCO1B1

SLCO1B1: A Potential Drug Target and Biomarker

Sodium-independent organic anion-transporting polypeptide 2 (SLCO1B1) is a protein that is expressed in various tissues and organs in the human body. It plays a critical role in the transport of organic anions across cell membranes, which are essential for maintaining the proper functioning of cells. SLCO1B1 is a potential drug target and biomarker due to its unique function and its potential to influence a variety of physiological processes in the body.

SLCO1B1 is a member of the SLCO gene family, which includes several related proteins that are involved in the transport of anions across cell membranes. These proteins are known as anion transporters and are responsible for maintaining the integrity of the cell membrane, as well as regulating the passage of essential ions and nutrients into or out of cells.

SLCO1B1 is expressed in a variety of tissues and organs, including the brain, heart, kidneys, and liver. It is also highly expressed in the placenta, which plays a critical role in the development and maintenance of fetal tissues. SLCO1B1 is involved in the transport of a variety of organic anions, including potassium, sodium, chloride, and bicarbonate.

SLCO1B1 has been shown to play a critical role in several physiological processes in the body. For example, SLCO1B1 is involved in the regulation of neuronal excitability and is thought to play a role in the transmission of electrical signals in the brain. It is also involved in the regulation of ion homeostasis, which is essential for maintaining the proper balance of ions in the body.

In addition to its role in ion homeostasis, SLCO1B1 is also involved in the regulation of cellular signaling processes. It has been shown to play a role in the regulation of neurotransmitter release and in the modulation of pain perception. SLCO1B1 may also be involved in the regulation of cell proliferation and may be a potential target for the development of cancer therapies.

SLCO1B1 is also a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and respiratory disorders. The expression of SLCO1B1 is often reduced in tissues and organs affected by these diseases, which may be used as a potential diagnostic or therapeutic target.

In conclusion, SLCO1B1 is a protein that is involved in the transport of organic anions across cell membranes and plays a critical role in several physiological processes in the body. Its unique function and its potential as a drug target and biomarker make it an attractive target for further research and development. Further studies are needed to fully understand the role of SLCO1B1 in the regulation of cellular processes and to explore its potential as a drug target and biomarker.

Protein Name: Solute Carrier Organic Anion Transporter Family Member 1B1

Functions: Mediates the Na(+)-independent uptake of organic anions (PubMed:10358072, PubMed:15159445, PubMed:17412826). Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (dehydroepiandrosterone 3-sulfate, 17-beta-glucuronosyl estradiol, and estrone 3-sulfate), as well as eicosanoids (prostaglandin E2, thromboxane B2, leukotriene C4, and leukotriene E4), and thyroid hormones (T4/L-thyroxine, and T3/3,3',5'-triiodo-L-thyronine) (PubMed:10358072, PubMed:10601278, PubMed:10873595, PubMed:12568656, PubMed:15159445, PubMed:15970799, PubMed:16627748, PubMed:17412826, PubMed:12196548, PubMed:11159893, PubMed:19129463, PubMed:26979622). Can take up bilirubin glucuronides from plasma into the liver, contributing to the detoxification-enhancing liver-blood shuttling loop (PubMed:22232210). Involved in the clearance of endogenous and exogenous substrates from the liver (PubMed:10358072, PubMed:10601278). Transports coproporphyrin I and III, by-products of heme synthesis, and may be involved in their hepatic disposition (PubMed:26383540). May contribute to regulate the transport of organic compounds in testes across the blood-testis-barrier (Probable). Can transport HMG-CoA reductase inhibitors (also known as statins), such as pravastatin and pitavastatin, a clinically important class of hypolipidemic drugs (PubMed:10601278, PubMed:15970799, PubMed:15159445). May play an important role in plasma and tissue distribution of the structurally diverse chemotherapeutic drug methotrexate (PubMed:23243220). May also transport antihypertension agents, such as the angiotensin-converting enzyme (ACE) inhibitor prodrug enalapril, and the highly selective angiotensin II AT1-receptor antagonist valsartan, in the liver (PubMed:16627748, PubMed:16624871). Shows a pH-sensitive substrate specificity towards prostaglandin E2 and T4 which may be ascribed to the protonation state of the binding site and leads to a stimulation of substrate transport in an acidic microenvironment (PubMed:19129463). Hydrogencarbonate/HCO3(-) acts as the probable counteranion that exchanges for organic anions (PubMed:19129463)

The "SLCO1B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLCO1B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets